🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Steven Knapper

Cardiff University

ORCID: 0000-0002-6405-4441

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes”.

Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromes

American Journal of Hematology(2023)10.1002/ajh.27161

N/A

0.587DataRank · unranked

49 citations

Jordi Esteve, Kimmo Porkka, Steven Knapper, Elie Traer, Sebastian Scholl +22 more

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.12.08.570880

N/A

0DataRank · unranked

4 citations

BH Yip, Giulia Orlando, Hemant Goyal, Simeng Wen, Jing Wen +27 more

Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A

Nature Genetics(2025)10.1038/s41588-025-02190-6

N/A

0DataRank · unranked

9 citations

Bon Ham Yip, Giulia Orlando, Jeremy Q. Wen, Sean Wen, Harsh Goyal +36 more